• Capricor Therapeutics (NASDAQ:CAPR) is conducting a public offering of common stock to fund the advancement of its product candidates, including Deramiocel for DMD.
• Analysts from Maxim Group and H.C. Wainwright have set optimistic price targets for CAPR, suggesting a potential increase of approximately 98.56% and 99.65%, respectively.
• The company's stock has shown volatility but maintains a strong market capitalization of approximately $1.23 billion, indicating significant investor interest.

Capricor Therapeutics, trading on NASDAQ:CAPR, is a biotechnology company focused on developing innovative cell and exosome-based therapeutics. The company is currently in the spotlight due to its proposed public offering of common stock. This offering is managed by Piper Sandler and Oppenheimer & Co., who are serving as joint book-running managers. The proceeds are earmarked for advancing Capricor's product candidates, including Deramiocel, which is in late-stage clinical development for Duchenne muscular dystrophy (DMD).

Capricor's strategic move to offer additional shares comes at a time when analysts are optimistic about its stock performance. On December 4, 2025, Maxim Group set a price target of $50 for CAPR, which was trading at $25.18 at the time. This suggests a potential increase of approximately 98.56%. Similarly, H.C. Wainwright set a price target of $60 on December 3, 2025, when the stock was priced at $29.95, indicating a potential rise of about 99.65%.

The company's current stock price is $26.89, reflecting a recent increase of approximately 5.87%. The stock has shown volatility, with a daily range between $26.01 and $28.63. Over the past year, CAPR has experienced significant fluctuations, reaching a high of $40.37 and a low of $4.30. This volatility is typical for biotechnology stocks, which are often influenced by clinical trial results and regulatory news.

Capricor's market capitalization is approximately $1.23 billion, with a trading volume of 7,007,389 shares. This indicates a strong interest in the stock, likely driven by the company's promising pipeline and strategic partnerships. Notably, Capricor has an agreement with Nippon Shinyaku Co., Ltd. for the commercialization of Deramiocel in the U.S. and Japan, pending regulatory approval. This partnership could significantly enhance Capricor's market reach and revenue potential.